PMC8695792_01
Treatment process of patient 1 (A), patient 2 (B) and patient 3 (C). CR, complete remission; IA, cytarabine 100 mg/m2 continuous infusion day1-7, idarubicin 12 mg/m2 day1-3; HiDAC, cytarabine 2 g/m2 over 3 h every 12 h on day1-3; CAG, cytarabine 10 mg/m2 every 12 h, day1-14; aclarubicin 5-7 mg/m2, daily on day1-8; and concurrent use of G-CSF 200 microg/m2/day; VA, venetoclax once daily (100 mg day1, 200 mg day2, 400 mg day3-28) and azacitidine 75 mg/m2 day1-7; VAC, venetoclax once daily (100 mg day1, 200 mg day2, 400 mg day3-21), azacitidine 75 mg/m2 daily day1-7, chidamide 5 mg daily day1-7.
fonc-11-797941-g001.jpg
PMC8695792_03_fonc-11-797941-g001.jpg
f1
Treatment process is shown in  Figure 1C .
PMC8695792_02
Treatment process of patient 1 (A), patient 2 (B) and patient 3 (C). CR, complete remission; IA, cytarabine 100 mg/m2 continuous infusion day1-7, idarubicin 12 mg/m2 day1-3; HiDAC, cytarabine 2 g/m2 over 3 h every 12 h on day1-3; CAG, cytarabine 10 mg/m2 every 12 h, day1-14; aclarubicin 5-7 mg/m2, daily on day1-8; and concurrent use of G-CSF 200 microg/m2/day; VA, venetoclax once daily (100 mg day1, 200 mg day2, 400 mg day3-28) and azacitidine 75 mg/m2 day1-7; VAC, venetoclax once daily (100 mg day1, 200 mg day2, 400 mg day3-21), azacitidine 75 mg/m2 daily day1-7, chidamide 5 mg daily day1-7.
fonc-11-797941-g001.jpg
PMC8695792_03_fonc-11-797941-g001.jpg
f1
Treatment process is shown in  Figure 1C .
PMC8695792_03
Treatment process of patient 1 (A), patient 2 (B) and patient 3 (C). CR, complete remission; IA, cytarabine 100 mg/m2 continuous infusion day1-7, idarubicin 12 mg/m2 day1-3; HiDAC, cytarabine 2 g/m2 over 3 h every 12 h on day1-3; CAG, cytarabine 10 mg/m2 every 12 h, day1-14; aclarubicin 5-7 mg/m2, daily on day1-8; and concurrent use of G-CSF 200 microg/m2/day; VA, venetoclax once daily (100 mg day1, 200 mg day2, 400 mg day3-28) and azacitidine 75 mg/m2 day1-7; VAC, venetoclax once daily (100 mg day1, 200 mg day2, 400 mg day3-21), azacitidine 75 mg/m2 daily day1-7, chidamide 5 mg daily day1-7.
fonc-11-797941-g001.jpg
PMC8695792_03_fonc-11-797941-g001.jpg
f1
Treatment process is shown in  Figure 1C .